CN1345240A - 用替莫唑胺改善癌症治疗 - Google Patents

用替莫唑胺改善癌症治疗 Download PDF

Info

Publication number
CN1345240A
CN1345240A CN00805865A CN00805865A CN1345240A CN 1345240 A CN1345240 A CN 1345240A CN 00805865 A CN00805865 A CN 00805865A CN 00805865 A CN00805865 A CN 00805865A CN 1345240 A CN1345240 A CN 1345240A
Authority
CN
China
Prior art keywords
temozolomide
day
period
kit
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00805865A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·拉加布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1345240A publication Critical patent/CN1345240A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN00805865A 1999-03-30 2000-03-27 用替莫唑胺改善癌症治疗 Pending CN1345240A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28134899A 1999-03-30 1999-03-30
US09/281,348 1999-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011100359769A Division CN102160864A (zh) 1999-03-30 2000-03-27 用替莫唑胺改善癌症治疗

Publications (1)

Publication Number Publication Date
CN1345240A true CN1345240A (zh) 2002-04-17

Family

ID=23076905

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00805865A Pending CN1345240A (zh) 1999-03-30 2000-03-27 用替莫唑胺改善癌症治疗
CN2011100359769A Pending CN102160864A (zh) 1999-03-30 2000-03-27 用替莫唑胺改善癌症治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011100359769A Pending CN102160864A (zh) 1999-03-30 2000-03-27 用替莫唑胺改善癌症治疗

Country Status (18)

Country Link
EP (1) EP1165071B1 (https=)
JP (2) JP2002540148A (https=)
CN (2) CN1345240A (https=)
AR (1) AR023185A1 (https=)
AT (1) ATE310515T1 (https=)
AU (1) AU780892B2 (https=)
BR (1) BR0009380A (https=)
CA (1) CA2368614C (https=)
DE (1) DE60024243T2 (https=)
DK (1) DK1165071T3 (https=)
ES (1) ES2251987T3 (https=)
HK (1) HK1044111B (https=)
HU (1) HUP0200805A3 (https=)
NO (1) NO330651B1 (https=)
NZ (1) NZ536302A (https=)
TW (1) TWI276434B (https=)
WO (1) WO2000057867A2 (https=)
ZA (1) ZA200107736B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028534A1 (fr) * 2002-09-29 2004-04-08 Tianjin Tasly Group Co., Ltd. Systeme de liberation controlee contenant temozolomide
WO2006024238A1 (en) * 2004-09-02 2006-03-09 Tianjin North Pharma Sci-Tech Co., Ltd. The pharmaceutical composition containing temozolomide-8-carboxylic esters and the use of the temozolomide-8-carboxylic esters for manufacture of the anti-tumour medicine
CN1299772C (zh) * 2004-10-14 2007-02-14 孔庆忠 一种抗癌药物组合物
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN102526038A (zh) * 2011-01-12 2012-07-04 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN101460151B (zh) * 2006-04-05 2013-11-20 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐
CN107397735A (zh) * 2017-07-28 2017-11-28 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) * 2023-11-24 2024-01-05 郑州德迈药业有限公司 一种替莫唑胺制剂及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
JP5199263B2 (ja) * 2006-09-29 2013-05-15 シプラ・リミテッド テモゾロミドと類似体を調製するための改善された方法
US20140005160A1 (en) * 2010-12-01 2014-01-02 Hooshmand SHESHBARADARAN Method for Treating Refractory Cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2233544A1 (en) * 1995-10-04 1997-04-10 Schering Corporation Combination temozolomide and alpha-ifn for the treatment of advanced cancer
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
CA2184546A1 (en) * 1996-07-31 1998-02-01 Margaret H. Dugan Method for treating pediatric high grade astrocytoma including brain stem glioma

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821913B2 (en) 2002-09-29 2014-09-02 Tasly Holding Group Co., Ltd. Controlled releases system containing temozolomide
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
RU2322979C2 (ru) * 2002-09-29 2008-04-27 Тианцзин Тейсли Груп Ко., Лтд. Система контролируемого высвобождения, содержащая темозоломид
WO2004028534A1 (fr) * 2002-09-29 2004-04-08 Tianjin Tasly Group Co., Ltd. Systeme de liberation controlee contenant temozolomide
WO2006024238A1 (en) * 2004-09-02 2006-03-09 Tianjin North Pharma Sci-Tech Co., Ltd. The pharmaceutical composition containing temozolomide-8-carboxylic esters and the use of the temozolomide-8-carboxylic esters for manufacture of the anti-tumour medicine
CN1299772C (zh) * 2004-10-14 2007-02-14 孔庆忠 一种抗癌药物组合物
CN101460151B (zh) * 2006-04-05 2013-11-20 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN102526038A (zh) * 2011-01-12 2012-07-04 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN107397735A (zh) * 2017-07-28 2017-11-28 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN107397735B (zh) * 2017-07-28 2020-07-10 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) * 2023-11-24 2024-01-05 郑州德迈药业有限公司 一种替莫唑胺制剂及其制备方法

Also Published As

Publication number Publication date
HK1044111A1 (en) 2002-10-11
AR023185A1 (es) 2002-09-04
DE60024243D1 (de) 2005-12-29
BR0009380A (pt) 2001-12-26
NO20014725L (no) 2001-11-13
HUP0200805A2 (hu) 2002-07-29
DE60024243T2 (de) 2006-08-17
CA2368614C (en) 2008-07-22
NO20014725D0 (no) 2001-09-28
ES2251987T3 (es) 2006-05-16
NO330651B1 (no) 2011-05-30
HK1044111B (en) 2006-02-24
ATE310515T1 (de) 2005-12-15
WO2000057867A2 (en) 2000-10-05
AU3924400A (en) 2000-10-16
NZ536302A (en) 2006-05-26
ZA200107736B (en) 2003-02-26
EP1165071B1 (en) 2005-11-23
WO2000057867A3 (en) 2001-04-19
JP2002540148A (ja) 2002-11-26
EP1165071A2 (en) 2002-01-02
AU780892B2 (en) 2005-04-21
JP2007169297A (ja) 2007-07-05
TWI276434B (en) 2007-03-21
CA2368614A1 (en) 2000-10-05
DK1165071T3 (da) 2006-02-20
CN102160864A (zh) 2011-08-24
HUP0200805A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
CN1345240A (zh) 用替莫唑胺改善癌症治疗
US5939098A (en) Cancer treatment with temozolomide
EP2877457B1 (en) Cystathionine-gamma-lyase (cse) inhibitors
Sekhon Metalloid compounds as drugs
US20100160433A1 (en) Treatment of neurodegenerative and cardiovascular disorders
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
CN1376064A (zh) 具有治疗学有用性质的吲哚基－3－乙醛酸衍生物
US6346524B1 (en) Cancer treatment with temozolomide
JP2021522345A (ja) 新規なｍｃｔ４阻害剤及びその使用
CA2435921A1 (en) Method of cancer therapy
CN1302780C (zh) 烷基胆碱磷酸在制备用抗肿瘤药之前和/或期间治疗肿瘤的药物中的应用
ES2278702T3 (es) Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol.
MXPA01009926A (en) Improved cancer treatment with temozolomide
RU2010139840A (ru) Комбинация противораковых агентов
PT858341E (pt) Terapeutica de combinacao para cancro avancado compreendendo temozolomida e cisplatina
CN113274394A (zh) 一种治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌的药物组合物
WO2020207344A1 (zh) 匹莫齐特和甲氨蝶呤的药物组合及其应用
US20260084978A1 (en) Process for producing atomic quantum clusters derivatives
RU2003102292A (ru) Способ анестезии при онкохирургических операциях на органах брюшной полости
US20250339429A1 (en) Methods of treating ulk3-associated cancers
CN104940212A (zh) 地塞米松用于抑制或治疗转移性或耐药性肿瘤的用途
JPWO2020222892A5 (https=)
Staff Cottonseed compound shows promise in battling lethal brain cancer, says Fiveash
MX2011006253A (es) Combinacion antitumoral que asocia ave8062 y docetaxel.
WO2016191559A1 (en) Palladium lipoic acid complex formulation as an adjunct in radiotherapy

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20020417